The dynamic multiple sclerosis (MS) market in the United States features more than a dozen high-cost branded (and one generic) disease-modifying therapies (DMTs) and an active pipeline. As the …
The primary goals of treatment of Sjögren’s syndrome (SS) are to relieve the hallmark sicca symptoms and minimize the impact and progression of systemic disease manifestations. Although an array…
Beta thalassemia is a rare genetic blood disorder characterized by a substantial reduction in or lack of β-globin protein, which results in chronic anemia, failure to thrive, jaundice, pallor,…
DRG’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key non-alcoholic fatty liver disease patient populations covering 171…
DRG’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key systemic lupus erythematosus patient populations covering 171 countries…
The shifting multiple sclerosis (MS) therapy market continues to evolve as new disease-modifying therapies (DMTs) expand treatment choices. Standout Ocrevus (Roche/Genentech) continues to transform…
Obesity is a significant public health concern and a growing epidemic in the G7 countries. The body of evidence highlighting the physical and economic impact of obesity on society is steadily…
Pulmonary hypertension (PH) is a devastating disease with high levels of morbidity and mortality and no cure. Despite the disease’s rarity, the potential commercial opportunities for drugs…
September 2019Physicians treating renal anemia are limited to iron supplements and erythropoiesis-stimulating agents (ESAs), which, although effective, have significant drawbacks. The hypoxia-…
Diabetic nephropathy (DN), also known as diabetic kidney disease, refers to kidney function damage caused by diabetes. DN is a leading cause of chronic kidney disease (CKD) and is associated with…
Autosomal dominant polycystic kidney disease (ADPKD) is a genetic disorder characterized by the development and progressive enlargement of fluid-filled cysts in the kidneys. Particularly in the…
Multiple well-established therapies are currently available to treat ulcerative colitis (UC) in Europe. TNF-α inhibitors such as Janssen / Merck’s Remicade and AbbVie / Eisai’s Humira helped…
DRG’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key type 1 diabetes patient populations covering 171 countries and more than…
The biosimilar/noninnovator sector of the endocrinology market is evolving. Eli Lilly/Boehringer Ingelheim’s Abasaglar/Basaglar was the first biosimilar/noninnovator insulin glargine to launch in…
The treatment of renal cell carcinoma has long been dominated by targeted treatments, including mTOR and angiogenesis inhibitors. However, the introduction of immune checkpoint inhibitors has…